NeoRx Corp. of Seattle announced last week that its pre-targeting technology for delivering radioactivity specifically totumors is 10 times more effective than conventionallyadministered radioimmunotherapy (RIT) in animals. NeoRx's(NASDAQ:NERX) results demonstrate that uptake ofradioactivity by the tumor is immediate and that non-tumorbound radiation disappears rapidly from the body. Inconventional RIT, the radioactivity accumulates gradually inthe tumor, and is gradually eliminated from the body. Thus,pre-targeting is safer and more efficacious than RIT.

"If the vast improvement in the efficacy/safety ratio caused bypre-targeting is reproducible in humans, it should provideeven better anti-tumor effects than produced withconventional RIT and with negligible toxicity," said PaulAbrams, NeoRx's president and chief executive officer.

(c) 1997 American Health Consultants. All rights reserved.